5d 1m 3m 1y 5y 10y
There are 4 articles on this stock available only to PRO subscribers.
There are no Transcripts on SNTI.
Senesco Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South AfricaBusiness Wire (Mar 12, 2014)
Business Wire (Mar 10, 2014)
Business Wire (Feb 18, 2014)
Business Wire (Jan 9, 2014)
Business Wire (Dec 30, 2013)
Business Wire (Dec 12, 2013)
SNTI vs. ETF Alternatives
Tuesday, Feb 187:20 AM
Monday, Dec 302013, 10:26 AM
Monday, Dec 302013, 10:26 AM| 3 Comments
- Senesco Technologies (SNTI +5.1%) agrees to terms and executes a non-binding LoI to merge with privately-held biotech firm Fabrus on an approximately 50-50 basis. A definitive agreement is expected in "early 2014."
- Fabrus aims to expand the impact of antibodies aimed at drug targets that are resistant to traditional antibody discovery methods. It has 2 collaborations with "large pharma and biotech companies" and an internal pipeline of antibodies targeting renal cell carcinoma and inflammation.
- CEO Leslie Browne: "Fabrus antibodies could complement our eIF5A gene regulatory platform, which has been shown to kill cancer cells, by directing nanoparticle-based therapeutics to the cells of interest."
- Making things more interesting: Phillip Frost's Frost Gamma Investments Trust, which recently made an investment in Senesco Technologies as detailed by SA Pro's John H. Ford, made an investment in Fabrus back in 2010.
Monday, Nov 192012, 4:39 PMSenesco Technologies (SNT) has received verbal notice from the NYSE of the exchange's decision to delist the company's common stock, effective prior to the open of trading on Wednesday, November 21. Upon delisting, the company intends to have its common stock quoted on the over-the-counter securities market. |Monday, Nov 192012, 4:39 PM| Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.